-
Product Hopping
While new formulations of drugs can provide benefits to patients, in some cases new formulations are introduced toward the end of a drug's patent or exclusivity, a practice often referred to as "product hopping".
-
Drug Prices are "Unreasonable"
Americans support government action to curb prescription drug prices
-
Biopharmaceutical Intellectual Property Challenges
Practices that undermine biopharmaceutical innovation.
-
Spending Money
Who are the largest investors in U.S. medical and health R&D?
-
Retail Prices for Widely Used Brand Name Drugs in America
Brand name drug price hikes are an industry-wide phenomenon.
-
Minimal Benefits, Maximum Costs
What do cancer drugs improve?
-
The Principles of Free Pricing in Germany
The law reforming the pharmaceutical market in Germany (ArzneimittelmarktNeuordnungsgesetz – AMNOG) took effect in January 2011.
-
Observations in the Treatment of Multiple Sclerosis
In the United States, list prices of on-patent medicines are rapidly increasing in some therapeutic areas.
-
A Review of Orphan Drugs
A report by the US GAO on the Trump Administration's handling of the Orphan Drug Act.
-
Degrees of Matching
A look at the distribution of drugs across Europe.
-
Enforcing Competition
Two agencies, one common goal.
-
A New Old Problem?
Older cancer drugs, higher new prices.
-
Dying to Survive
In wake of hit movie depicting plight of cancer patient, Chine moves to slash prices.
-
America's Biotech Problem
The prices of biologics have consistently increased over the rate-of-inflation for the past forty years.
-
The President Promised
Well, it hasn't happened.
